GenMark Diagnostics (GNMK) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GenMark Diagnostics Reports Fourth Quarter and Full Year 2016 Results
February 28, 2017 4:05 PM ESTFourth Quarter Revenue Increased 13% Versus Prior Year to $14.9 million
Full Year Revenue Grew by 25% to $49.3 million
Submitted FDA 510(k) Applications for ePlex Instrument and Respiratory Pathogen Panel
Ended 2016 with More Than 55 Customer Agreements, Representing Over 85 ePlex Instruments
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2016.
Revenue for the fourth quarter of 2016 was $14.9... More
